Literature DB >> 29153675

sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?

Fiona Brownfoot1, Tu'uhevaha Kaitu'u-Lino1, Sally Beard1, Stephen Tong1, Natalie Hannan2.   

Abstract

Soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are increased in the circulation of women with preeclampsia. We examined whether they differ in concentration between plasma and serum samples. Maternal blood was collected and processed for serum and plasma, from 28 women with preterm preeclampsia and 18 gestation matched controls (<34weeks). Significantly higher sFlt-1 was detected in preeclamptic serum compared to plasma. Significantly higher levels of sENG were identified in serum compared to plasma from control pregnancies. Thus these data show the sample type (serum or plasma) needs to be consistent within comparisons for both sFlt-1 and sENG.
Copyright © 2017 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29153675     DOI: 10.1016/j.preghy.2017.07.138

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  3 in total

1.  Optimizing Measurement of Vascular Endothelial Growth Factor in Small Blood Samples of Premature Infants.

Authors:  Claudia C Lopez Yomayuza; Klaus T Preissner; Birgit Lorenz; Knut Stieger
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

2.  Assessing the Role of Uric Acid as a Predictor of Preeclampsia.

Authors:  Ana I Corominas; Yollyseth Medina; Silvia Balconi; Roberto Casale; Mariana Farina; Nora Martínez; Alicia E Damiano
Journal:  Front Physiol       Date:  2022-01-13       Impact factor: 4.566

3.  The diagnosis values of serum STAT4 and sEng in preeclampsia.

Authors:  Luyan Zhang; Xuechun Li; Chengcheng Zhou; Zhengming You; Jianwei Zhang; Guomei Cao
Journal:  J Clin Lab Anal       Date:  2019-10-19       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.